Abstract
One potential mechanism for the effectiveness of organoselenium compounds against a number of cancer cell lines is the interaction of selenium with zinc signaling processes. Reducible selenium (rSe) compounds such as diselenides, selenenyl halides and seleninic acids release zinc from zinc fingers and metallothionein. Based upon a review of the literature, two key mechanisms are discussed: the stoichiometric displacement of zinc by selenium and the catalytic oxidation of Cys thiolates by reducible organoselenium compounds produced in situ. Initial DFT calculations of the strengths of interactions between rSe and a Cys2His2-type ZF model are presented to contrast the reactivity of reducible selenium compounds with sulfur and tellurium analogues.
Keywords: Selenium, zinc finger proteins, zinc signaling, cancer prevention, density-functional theory, molecular modeling
Current Chemical Biology
Title:Oxidation of Zinc-Sulfur Centers by Reducible Organoselenium Compounds: A Review and Bonding Perspective
Volume: 7 Issue: 1
Author(s): Craig A. Bayse, Sean M. Whitty and Sonia Antony
Affiliation:
Keywords: Selenium, zinc finger proteins, zinc signaling, cancer prevention, density-functional theory, molecular modeling
Abstract: One potential mechanism for the effectiveness of organoselenium compounds against a number of cancer cell lines is the interaction of selenium with zinc signaling processes. Reducible selenium (rSe) compounds such as diselenides, selenenyl halides and seleninic acids release zinc from zinc fingers and metallothionein. Based upon a review of the literature, two key mechanisms are discussed: the stoichiometric displacement of zinc by selenium and the catalytic oxidation of Cys thiolates by reducible organoselenium compounds produced in situ. Initial DFT calculations of the strengths of interactions between rSe and a Cys2His2-type ZF model are presented to contrast the reactivity of reducible selenium compounds with sulfur and tellurium analogues.
Export Options
About this article
Cite this article as:
A. Bayse Craig, M. Whitty Sean and Antony Sonia, Oxidation of Zinc-Sulfur Centers by Reducible Organoselenium Compounds: A Review and Bonding Perspective, Current Chemical Biology 2013; 7 (1) . https://dx.doi.org/10.2174/2212796811307010006
DOI https://dx.doi.org/10.2174/2212796811307010006 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Malnutrition in Older Persons with Mobility Limitations
Current Pharmaceutical Design Targeting Carcinogen Metabolism by Dietary Cancer Preventive Compounds
Current Cancer Drug Targets The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Subject Index To Volume 2
Current Hypertension Reviews Bisphosphonate Therapy for Patients with Breast Cancer
Current Cancer Therapy Reviews L-Asparaginase and Inhibitors of Glutamine Synthetase Disclose Glutamine Addiction of β-Catenin-Mutated Human Hepatocellular Carcinoma Cells
Current Cancer Drug Targets Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Editorial [Hot Topic: Advanced Imagings of Wallerian Degeneration, Pancreatobiliary System, Uterine Cervical Cancer, Periventricular Leukomalacia, Living Cells as well as MR Contrast Agent and QC of SPECT/CT]
Current Medical Imaging Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Penile Rehabilitation After Radical Prostatectomy
Current Drug Targets Emerging Role of Stem Cells - Derived Exosomes as Valuable Tools for Cardiovascular Therapy
Current Stem Cell Research & Therapy Approaches to Targeting Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Antisense Technologies Targeting Fatty Acid Synthetic Enzymes
Recent Patents on Anti-Cancer Drug Discovery Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma
Current Cancer Therapy Reviews DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
Current Drug Metabolism Acknowledgements to Reviewers:
Current Cancer Drug Targets